Pharmacokinetics of ICG and HPPH-car for the Detection of Normal and Tumor Tissue Using Fluorescence, Near-infrared Reflectance Imaging: A Case Study¶

Abstract We present in vivo fluorescent, near-infrared (NIR), reflectance images of indocyanine green (ICG) and carotene-conjugated 2-devinyl-2-(1-hexyloxyethyl) pyropheophorbide (HPPH-car) to discriminate spontaneous canine adenocarcinoma from normal mammary tissue. Following intravenous administration of 1.0 mg kg−1 ICG or 0.3 mg kg−1 HPPH-car into the canine, a 25 mW, 778 nm or 70 mW, 660 nm laser diode beam, expanded by a diverging lens to approximately 4 cm in diameter, illuminated the surface of the mammary tissue. Successfully propagating to the tissue surface, ICG or HPPH-car fluorescence generated from within the tissue was collected by an image-intensified, charge-coupled device camera fitted with an 830 or 710 nm bandpass interference filter. Upon collecting time-dependent fluorescence images at the tissue surface overlying both normal and diseased tissue volumes, and fitting these images to a pharmacokinetic model describing the uptake (wash-in) and release (wash-out) of fluorescent dye, the pharmacokinetics of fluorescent dye was spatially determined. Mapping the fluorescence intensity owing to ICG indicates that the dye acts as a blood pool or blood persistent agent, for the model parameters show no difference in the ICG uptake rates between normal and diseased tissue regions. The wash-out of ICG was delayed for up to 72 h after intravenous injection in tissue volumes associated with disease, because ICG fluorescence was still detected in the diseased tissue 72 h after injection. In contrast, HPPH-car pharmacokinetics illustrated active uptake into diseased tissues, perhaps owing to the overexpression of LDL receptors associated with the malignant cells. HPPH-car fluorescence was not discernable after 24 h. This work illustrates the ability to monitor the pharmacokinetic delivery of NIR fluorescent dyes within tissue volumes as great as 0.5–1 cm from the tissue surface in order to differentiate normal from diseased tissue volumes on the basis of parameters obtained from the pharmacokinetic models.

[1]  J. S. Reynolds,et al.  Imaging of Spontaneous Canine Mammary Tumors Using Fluorescent Contrast Agents , 1999, Photochemistry and photobiology.

[2]  Stefan Andersson-Engels,et al.  Optical detection of human urinary bladder carcinoma utilising tissue autoflurescence and protoporphyrin IX-induced fluorescence following low dose ALA instillation , 1995, European Conference on Biomedical Optics.

[3]  M S Patterson,et al.  Imaging of fluorescent yield and lifetime from multiply scattered light reemitted from random media. , 1997, Applied optics.

[4]  William R. Potter,et al.  Optical methods for in-vivo pharmacokinetics (Invited Paper) , 1992, Photonics West - Lasers and Applications in Science and Engineering.

[5]  H Szmacinski,et al.  Frequency domain imaging of absorbers obscured by scattering. , 1992, Journal of photochemistry and photobiology. B, Biology.

[6]  L. Tierney,et al.  A Canine Model of Familial Mammary Gland Neoplasia , 1998, Veterinary pathology.

[7]  B. Pogue,et al.  PHOTODYNAMIC THERAPY OF CANCER , 2022 .

[8]  R Cubeddu,et al.  Fluorescence Lifetime Imaging of Experimental Tumors in Hematoporphyrin Derivative‐Sensitized Mice , 1997, Photochemistry and photobiology.

[9]  M J Eppstein,et al.  Biomedical optical tomography using dynamic parameterization and bayesian conditioning on photon migration measurements. , 1999, Applied optics.

[10]  B. Wilson,et al.  In Vivo Fluorescence Spectroscopy and Imaging for Oncological Applications , 1998, Photochemistry and photobiology.

[11]  Thomas S. Mang,et al.  Fluorescence detection of premalignant, malignant, and micrometastatic disease using hexylpyropheophorbide , 1994, Other Conferences.

[12]  W R Greco,et al.  An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. , 1997, Cancer research.

[13]  Irving J. Bigio,et al.  Elastic-scattering spectroscopy for quantitative measurement of chemotherapy and PDT drug concentrations in vivo , 1999, European Conference on Biomedical Optics.

[14]  M S Patterson,et al.  Modeling of photosensitizer fluorescence emission and photobleaching for photodynamic therapy dosimetry. , 1998, Applied optics.

[15]  Joseph R. Lakowicz,et al.  Lifetime‐selective fluorescence imaging using an rf phase‐sensitive camera , 1991 .

[16]  C. L. Hutchinson,et al.  Fluorescence and Absorption Contrast Mechanisms for Biomedical Optical Imaging Using Frequency‐Domain Techniques , 1997, Photochemistry and photobiology.

[17]  Stefan Andersson-Engels,et al.  Clinical detection studies of Barrett's metaplasia and oesophageal adenocarcinoma by means of laser-induced fluorescence , 1995, European Conference on Biomedical Optics.

[18]  Kevin M. Smith,et al.  Alkyl Ether Analogs of Chlorophyll‐a Derivatives: Part 1. Synthesis, Photophysical Properties and Photodynamic Efficacy , 1996, Photochemistry and photobiology.

[19]  K Svanberg,et al.  Kinetic fluorescence studies of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation in basal cell carcinomas. , 1999, Journal of photochemistry and photobiology. B, Biology.

[20]  A G Yodh,et al.  Fluorescent heterogeneities in turbid media: limits for detection, characterization, and comparison with absorption. , 1998, Applied optics.